Recruiting studies: Egfr Mutant Advanced Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT06355609 Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060 Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06363734 MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Phase 1 · 1 location(s) · Emory University · NCT04762199 Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
NA · 1 location(s) · Guangzhou University of Traditional Chinese Medicine · NCT07348965 A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Phase 1/Phase 2 · 10 location(s) · J Ints Bio · NCT05394831 Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor The
Phase 2 · 1 location(s) · Pusan National University Hospital · NCT07073365 Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patie
Phase 1 · 45 location(s) · BioNTech SE · NCT05142189 Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China
Phase 1 · 1 location(s) · Alpha Biopharma (Jiangsu) Co., Ltd. · NCT07620951 Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Phase 1/Phase 2 · 10 location(s) · Genprex, Inc. · NCT04486833 AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients
Phase N/A · 1 location(s) · Fudan University · NCT06604689 JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Phase 2 · 2 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT07518160 Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell L
Phase N/A · 9 location(s) · N-Power Medicine · NCT07028489 Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A L
Phase 2 · 454 location(s) · SWOG Cancer Research Network · NCT05642572 ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
Phase 2 · 1 location(s) · Fudan University · NCT06775743 A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-m
Phase N/A · 34 location(s) · Alpha Biopharma (Jiangsu) Co., Ltd. · NCT07143045 Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Ca
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07323056 Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Phase N/A · 1 location(s) · Hunan Province Tumor Hospital · NCT04324164 A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
Phase 1/Phase 2 · 5 location(s) · Henan Genuine Biotech Co., Ltd. · NCT07362940 Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Phase 2 · 26 location(s) · Sun Yat-sen University · NCT05334277 High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-g
Phase 2 · 1 location(s) · Jialei Wang · NCT06652048 EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT07637448

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.